Small molecule stimulators of innate immune receptors

先天免疫受体的小分子刺激剂

• 批准号: 8751021
• 负责人: DENNIS CARSON
• 金额: $ 212.02万
• 依托单位: CALIFORNIA UNIV SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8751021
• 关键词: Adjuvant; Antigens; B-Lymphocytes; Binding; Cells; Communicable Diseases; Contracts; Goals; Human; Immune system; Immunologic Adjuvants; Immunologic Receptors; Intramuscular; Lead; Libraries; Preclinical Testing; RNA Interference; Reporter; Research Personnel; Route; Specificity; T-Lymphocyte; TLR1 gene; Techniques; Technology; Vaccines; base; cell mediated immune response; high throughput screening; prevent; programs; receptor; small molecule; subcutaneous

The goals of the Innate Immune Receptors and Adjuvant Discovery program are to discover, characterize, and support preclinical testing of new adjuvant candidates based upon triggering of the human innate immune system. Adjuvants are defined as molecules that act via innate immune receptors to activate beneficial innate and/or adaptive (T and B cell-mediated) immune responses. Using high throughput screening techniques, investigators will screen compound libraries to identify potential adjuvant products that may be developed as components of antigen specific vaccines against infectious disease, or may serve as stand-alone agents that transiently prevent or treat infectious disease.

先天免疫受体和佐剂发现计划的目标是发现，表征和支持基于人类先天免疫系统触发的新佐剂候选物的临床前测试。佐剂被定义为通过先天免疫受体起作用以激活有益的先天和/或适应性（T和B细胞介导的）免疫应答的分子。使用高通量筛选技术，研究人员将筛选化合物库，以确定潜在的佐剂产品，这些产品可能被开发为针对传染病的抗原特异性疫苗的组分，或者可能作为暂时预防或治疗传染病的独立试剂。